ISRCTN16213127CompletedNot Applicable
Evaluation of the safety and efficacy of the Optimizer™ II and III systems with active fixation leads in subjects with heart failure resulting from systolic dysfunctio
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Impulse Dynamics Inc. (USA)
- Enrollment
- 250
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Age - subjects who are 18 years of age or older
- •2. Gender - subjects who are either male or female
- •3. Condition:
- •3.1. Subjects with moderate to severe heart failure as evidenced by a baseline peak oxygen uptake between 10 and 20 ml O2/min/kg
- •3.2. Subjects with baseline ejection fraction of 35% or less by echocardiography
- •3.3. Subjects who are on optimal medical therapy for heart failure, consisting of the appropriate medications, doses and duration of treatment based on standard of care for the institution. Guidelines for defining optimal medical therapy and minimum durations of treatment may vary among participating centers. However, the following set of guidelines regarding minimum duration of treatment shall be required for each class of drugs:
- •3.3.1. Diuretics - sufficient dose for at least two weeks so that the subject is clinically euvolemic
- •3.3.2. Angiotensin converting enzyme (ACE)-inhibitor or angiotensin II receptor blocker at a stable dose for at least two weeks
- •3.3.3. Digoxin for at least two weeks
- •4. Beta-blocker:
- •4.1. If the subject is already taking a beta-blocker, he or she must have reached the clinically indicated target dose (i.e. no further dose titration) and must have been on a stable dose for a minimum of two weeks
- •4.2. If the subject is not already taking a beta-blocker, the subject and the referring physician must agree that a beta-blocker will not be started until the subject completes the six-month follow-up visit of the study
- •5. Subjects may have an implanted pacemaker. Subjects may have an implantable cardioverter defibrillator (ICD) system with true or dedicated bipolar sensing. Subjects may have dual chamber pacemakers and dual chamber ICDs as long as the device was implanted a minimum of one month prior to enrollment. Subjects who have a documented history of non-sustained ventricular tachycardia or unexplained syncope shall be required to have evidence of non-inducibility on clinical electrophysiologic testing or have an implanted cardiac defibrillator (ICD).
- •6. Subjects who are otherwise eligible to participate in the study may undergo Optimizer™ pulse generator implantation at the same time as an ICD and/or pacemaker, but if the ICD or pacemaker is a dual chamber device, the Optimizer™ pulse generator cannot be activated for one month
- •7. Subjects who are willing and able to return for all follow-up visits
Exclusion Criteria
- •1. Subjects with a potentially correctible cause of heart failure, such as valvular heart disease or congenital heart disease
- •2. Subjects with evidence of active ischemia consisting of, for example, angina or electrocardiogram (ECG) changes during exercise testing)
- •3. Subjects who have been hospitalized within one month prior to enrolment for heart failure, which has required the use of intravenous diuretics or inotropic support
- •4. Subjects without an ICD who have a documented history of sustained ventricular tachycardia (VT), or who have an indication for and ICD and are not scheduled for ICD implantation
- •5. Subjects with an ICD who have had appropriate ICD firing during the past one month
- •6. Subjects who have a clinically significant amount of ambient ectopy, defined as more than a total of 8,900 premature ventricular contractions (PVCs) per 24 hours on baseline Holter monitoring
- •7. Subjects with chronic atrial fibrillation or chronic atrial flutter
- •8. Subjects whose exercise tolerance is limited by a condition other than heart failure (e.g. angina, chronic obstructive pulmonary disease (COPD), peripheral vascular disease, orthopedic or rheumatologic conditions)
- •9. Subjects who are unable to participate in a six-minute walk and/or a cardiopulmonary stress test
- •10. Subjects who are scheduled for a coronary artery bypass grafting (CABG) or a percutaneous transluminal coronary angioplasty (PTCA) procedure, or who have undergone a CABG procedure within three months or a PTCA procedure within one month of enrolment
- •11. Subjects who, in the opinion of the principal investigator, have a clinical indication for bi-ventricular pacing
- •12. Subjects with a left ventricular pacing lead
- •13. Subjects who have had a myocardial infarction within three months of study enrolment
- •14. Subjects with mechanical tricuspid or aortic valves
- •15. Subjects with a prior heart transplant
- •16. Subjects already having an optimizer™ device
- •17. Subjects with a previously implanted ICD which employs unipolar or integrated bipolar sensing
- •18. Subjects who are participating in another experimental protocol
- •19. Subjects in vulnerable populations who are unable to provide informed consent
Investigators
Similar Trials
Not yet recruiting
Not Applicable
The evaluation of safety and efficacy of OptimosTM s sphincterotome in patient with biliary disease requiring endoscopic retrograde cholangiopancreatographyDiseases of the digestive systemKCT0004995Yonsei University Health System, Gangnam Severance Hospital200
Recruiting
Phase 1
Safety study to evaluate the usefulness of optimal needle guide(ONG) under ultrasound-guided CVCJPRN-UMIN000030631AMED16
Recruiting
Not Applicable
Evaluation of the safety and effectiveness of the MID- C system in adolescent idiopathic scoliosis.Surgical treatment of adolescent idiopathic scoliosis (AIS).NL-OMON21786VU University Medical Center, Amsterdam, The Netherlands33
Completed
Not Applicable
Evaluation of the safety and effectiveness of the MID-C/ApiFix system in adolescent idiopathic scoliosis.Spinal curvature1002837710005944NL-OMON43676Vrije Universiteit Medisch Centrum33
Completed
Not Applicable
Prospective evaluation of efficacy and safety of argon plasma coagulation therapy with submucosal injection prior to ablation in Barrett's esophagusC15.5Lower third of oesophagusDRKS00003369HSK Wiesbaden60